ARHGEF3-AS1

Across TCGA pan-cancer cohorts, ARHGEF3-AS1 RNA is linked to patient survival in 11 of 34 cancer types, making it the most broadly survival-associated ARHGEF3-AS1 data layer.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ARHGEF3-AS1 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARHGEF3-AS1 expression acts as an unfavorable survival marker, although some lineages such as BRCA and KIRC show a favorable association.

LUAD, COAD, and LUSC are the cancer types where ARHGEF3-AS1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	IV	0.104	0.611	.003	36	view →
COAD	OS	Tertile	III,IV	0.165	0.556	.012	27	view →
LUSC	OS	Tertile	All	0.391	0.749	<.001	27	view →
BRCA	OS	Tertile	III,IV	0.946	0.803	.013	24	view →
PCPG	OS	Tertile	All	0.505	0.946	<.001	24	view →
DLBC	OS	Tertile	All	0.053	0.936	<.001	18	view →
SKCM	DFS	Tertile	II,III,IV	0.220	0.711	.013	15	view →
KIRC	DFS	Tertile	IV	0.925	0.516	.036	12	view →
KIRP	DFS	Tertile	All	1.000	0.692	.045	12	view →
LGG	OS	Tertile	All	0.715	0.844	.028	12	view →
ESCA	OS	Quartile	III,IV	0.702	0.403	.013	9	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

ARHGEF3-AS1–LUAD (DFS)

Open the LUAD breakdown →